Peter Pliszka

The plaintiffs sought certification of a national class action against the defendants regarding alleged defects and failures to warn associated with Allergan breast implants, specifically concerning risks of BIA-ALCL, premature rupture, and ASIA/BII.

The court found that the plaintiffs met all the criteria under section 5(1) of the Class Proceedings Act, 1992, including demonstrating a plausible methodology for their claims through expert evidence, despite significant scientific debate.

The action was certified against all defendants, expanding a previous partial certification order.

In a certified class action regarding allegedly defective MINI Cooper vehicles, the defendants brought a motion seeking a declaration that the German defendant, BMW-AG, could produce documents using a 'layered approach' to comply with European and German privacy laws (GDPR).

This approach involved initially redacting all personal data.

The plaintiff opposed, arguing that Ontario's Rules of Civil Procedure required unredacted production.

The court held that the relevance scrutiny inherent in the Rules of Civil Procedure satisfies the 'Legitimate Interests Exception' under the foreign privacy laws.

The court ordered BMW-AG to produce documents in accordance with a modified Rule 30.03, allowing redactions only for privileged information and personal data that is not relevant to any issue in the action.

The plaintiff in a certified class action brought a refusals motion seeking to compel answers to questions refused during cross-examinations on the defendants' affidavits of documents.

The court dismissed the motion in its entirety, finding that the questions regarding the scope of documentary production, missing documents, and search terms were premature and irrelevant because the parties had not yet settled a discovery plan.

The court held that the scope of documentary discovery must be determined on the pending discovery plan motion before the adequacy of the affidavits of documents could be assessed.

The plaintiff sought court approval to dismiss his proposed class action regarding the recalled drug Valsartan.

Following a carriage agreement with another class action and discovering that one defendant did not manufacture the active ingredient, the plaintiff sought to dismiss the action against all defendants without costs.

The court approved the dismissal under section 29 of the Class Proceedings Act, 1992, finding no prejudice to putative class members as other actions were proceeding across Canada.

Following the dismissal of the plaintiffs' motion for certification in an emissions defeat device class action, the successful defendants sought costs totaling $965,012 on a partial indemnity basis.

The plaintiffs argued for a maximum award of $125,000, noting their own costs were $550,263.

The court fixed costs at $560,000 all-inclusive on a partial indemnity scale, finding this amount fair and reasonable given the complexity of the issues, the number of defendant groups, and the costs reasonably incurred by the plaintiffs themselves.

The plaintiffs brought a motion to certify a class action against the defendants regarding an alleged emissions defeat device in certain diesel-engine vehicles.

The defendants had already initiated a recall to repair the defeat device at no cost, rendering the vehicles compliant with emissions regulations.

The court dismissed the certification motion, finding that the plaintiffs failed to provide any evidence of compensable harm, such as paying a premium price or experiencing reduced fuel economy post-repair.

Without compensable harm, the court held that a class action would not advance the goals of access to justice, behaviour modification, or judicial economy.